Estimating the cost of new drug development: Is it really $802 million?

被引：551

作者：

Adams, CP ^{[1
]}

Brantner, VV ^{[1
]}

机构：

[1] Fed Trade Commiss, Bur Econ, Washington, DC 20580 USA

来源：

HEALTH AFFAIRS | 2006年 / 25卷 / 02期

关键词：

D O I：

10.1377/hlthaff.25.2.420

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

This paper replicates the drug development cost estimates of Joseph DiMasi and colleagues ("The Price of Innovation"), using their published cost estimates along with information on success rates and durations from a publicly available data set. For drugs entering human clinical trials for the first time between 1989 and 2002, the paper estimated the cost per new drug to be $868 million. However, our estimates vary from around $500 million to more than $2,000 million, depending on the therapy or the developing firm.

引用

页码：420 / 428

页数：9